

# 13<sup>th</sup> INTERNATIONAL FORUM ON MOOD AND ANXIETY DISORDERS

MONACO, 20-22 NOVEMBER, 2013



[www.ifmad.org](http://www.ifmad.org)

M. C. Escher "The Knot"



Final programme



## SCIENTIFIC COMMITTEE

### Chairman

Siegfried Kasper (*Austria*)

### Co-Chairman

Stuart A. Montgomery (*United Kingdom*)

### Scientific Advisers (invited)

C. Allgulander (*Sweden*), C.A. Altamura (*Italy*), C. Arango (*Spain*),  
D. Baldwin (*United Kingdom*), B. Bandelow (*Germany*), M. Bauer (*Germany*),  
P. Boyer (*Canada*), G.B. Cassano (*Italy*), K. Demyttenaere (*Belgium*),  
J. Den Boer (*The Netherlands*), T. Dinan (*Ireland*), E. Eriksson (*Sweden*),  
N. Fineberg (*United Kingdom*), T. Higuchi (*Japan*), S.H. Kennedy (*Canada*),  
D. Lecic Tosevski (*Serbia*), J.P. Lépine (*France*), M. Maj (*Italy*), A.A. Mathé (*Sweden*),  
J. Mendlewicz (*Belgium*), H.J. Möller (*Germany*), S. Pallanti (*Italy*),  
G. Papadimitriou (*Greece*), G. Papakostas (*USA*), Z. Rihmer (*Hungary*),  
T. Roth (*USA*), A. F. Schatzberg (*USA*), I. Schweitzer<sup>†</sup> (*Australia*), A. Serretti (*Italy*),  
D.J. Stein (*South Africa*), T. Svensson (*Sweden*), T. Suppes (*USA*), E. Vieta (*Spain*),  
D. Winkler (*Austria*), S. Yamawaki (*Japan*), A. Young (*UK*), J. Zohar (*Israel*)

## ORGANIZING SECRETARIAT



### PUBLI CREATIONS

74, Bd d'Italie - 98000 Monte-Carlo - Monaco

Ph. +377 97973555 - Fax +377 97973550

E-mail: [ifmad@publiccreations.com](mailto:ifmad@publiccreations.com)

Website: [www.ifmad.org](http://www.ifmad.org)

### Forum Venue



### FAIRMONT MONTE CARLO

12, Av. des Spéluges

98000 Monaco

Tel. + 377 93506500



Scientific Committee Organizing Secretariat Forum Venue	<b>2</b>
---	----------

Acknowledgements	<b>4</b>
------------------	----------

Welcome Letter	<b>5</b>
----------------	----------

Programme Overview	<b>6</b>
--------------------	----------

Scientific Programme	<b>7</b>
----------------------	----------

Posters	<b>13</b>
---------	-----------

Scientific Information / General Information	<b>26</b>
--	-----------



## ACKNOWLEDGEMENTS

*The Organizing Committee expresses their gratitude  
for their contribution of unrestricted educational grants*



**LUNDBECK**

*for their unrestricted grant as Sponsor of Symposia*



Pierre Fabre

**PIERRE FABRE MEDICAMENT**

*for their contribution as sponsor of the speaker's dinner*



**DIRECTION DU TOURISME ET DES CONGRES**

*for their contribution as sponsor of the Welcome Cocktail*



*To all prospective delegates,*

*It is a pleasure to welcome you in Monaco to the annual meeting of the International Forum on Mood and Anxiety Disorders (IFMAD).*

*The most useful feature about IFMAD meetings is that current clinical hot topics and new data are presented in a balanced format, adequately dissected and discussed in a collegiate atmosphere, and digested over dinner.*

*The meetings are always enjoyable and informative and along with the usual updates on new treatments this year's IFMAD will be an efficient way of catching up with the latest developments.*

*This year topics that will be addressed include the following: lithium medicine or myth, the hurtful brain, cognition as a treatment target in mood disorders, depression and cognitive and negative symptoms in schizophrenia, treatment resistant depression, treatment of MDD.*

*We are pleased to welcome you in Monaco and have you to give you the opportunity to keep with us again this year.*

Siegfried Kasper, Chairman

Stuart A. Montgomery, Co-Chairman

## PROGRAMME OVERVIEW

**Wednesday,  
November 20**

**Thursday,  
November 21**

**Friday,  
November 22**

**14.30/16.00**  
**SO 01** Lithium medicine  
or myth

**16.00/16.30**  
*Coffee break*

**16.30/18.00**  
**SO 02** The hurtful brain

**18.00/19.00**  
*Welcome cocktail*

**09.00/10.30**  
**SO 03** Recovery -  
the new treatment goal  
in depression? - A debate

**10.30/11.00**  
*Coffee break*

**11.00/12.30**  
**SO 04** Cognition as a treatment  
target in mood disorders

**12.30/13.30**  
*Lunch*

**13.30/15.00**  
**SO 05** Cognitive dysfunction  
in major depressive disorder  
- patient perceptions and  
objective measures

**15.00/16.30**  
**SO 06** Depression, cognitive  
and negative symptoms  
in schizophrenia: Underlying  
neurobiology and novel leads  
for pharmacological  
treatment

**16.30/16.45**  
*Coffee break*

**16.45/18.15**  
**SO 07** Adherence  
with treatment

**18.15/19.15**  
Meet the Expert

**09.00/10.30**  
**SO 08** The revised diagnostic  
criteria of mental disorders  
(DSM-5): bipolar disorder  
is bipolar again -  
revisiting the classics

**10.30/11.00**  
*Coffee break*

**11.00/12.30**  
**SO 09** Treatment  
resistant depression

**12.30/13.30**  
*Lunch*

**13.30/15.00**  
**SO 10** Treatment of  
Major Depressive Disorder

**15.00/16.30**  
**SO 11** Hot topics

**16.30/16.45**  
*End of meeting*



## WEDNESDAY, 20 November 2013

### 14.30-16.00 SO 01 LITHIUM MEDICINE OR MYTH

Chair: **T. DINAN (Ireland)**  
**S. MONTGOMERY (UK)**

**14.30-15.00 SO 0101** Lithium in acute treatment of bipolar disorder  
**Rasmus LICHT (Denmark)**

**15.00-15.30 SO 0102** Bipolar maintenance treatment  
**Heinz GRUNZE (United Kingdom)**

**15.30-16.00 SO 0103** Lithium: Still the gold standard for augmenting antidepressants?  
**Timothy DINAN (Ireland)**

► Please note that a 5' discussion with the speaker is foreseen at the end of each presentation.

### 16.00-16.30 **Coffee break**

### 16.30-18.00 SO 02 THE HURTFUL BRAIN

Chair: **J. DEN BOER (The Netherlands)**  
**R. LICHT (Denmark)**

**16.30-17.00 SO 0201** The comorbidity of pain, anxiety and depression  
**Hans-Ulrich WITTCHEN (Germany)**

**17.00-17.30 SO 0202** Explaining the co-occurrence of pain, anxiety and depression  
**Johan DEN BOER (The Netherlands)**

**17.30-18.00 SO 0203** Psychotropics as treatments for pain  
**Michael BACH (Germany)**

► Please note that a 5' discussion with the speaker is foreseen at the end of each presentation.

### 18.00-19.00 **Welcome cocktail**



### THURSDAY, 21 November 2013

#### 09.00-10.30 **SO 03 RECOVERY – THE NEW TREATMENT GOAL IN DEPRESSION? – A DEBATE**

Moderator: **A. WADE (UK)**

09.00-09.10 **Welcome and introduction**

09.10-09.30 **SO 0301** Is recovery a better treatment goal than remission?

**Koen DEMYTTENAERE (Belgium),**

**Thomas E. SCHLÄPFER (Germany)**

09.35-09.55 **SO 0302** What assessment tools should be used for evaluating whether the treatment goal has been achieved?

**Koen DEMYTTENAERE (Belgium),**

**Thomas E. SCHLÄPFER (Germany)**

10.00-10.20 **SO 0303** What would be the best approach to changing treatment for patients not achieving the treatment goal upon antidepressant therapy?

**Koen DEMYTTENAERE (Belgium),**

**Thomas E. SCHLÄPFER (Germany)**

10.25-10.30 Discussion and closing remarks

All sessions will be followed by a 5' session of Questions and Answers chaired by **Alan WADE (UK)**

10.30-11.00 **Coffee break**

#### 11.00-12.30 **SO 04 COGNITION AS A TREATMENT TARGET IN MOOD DISORDERS**

Chair: **H.J. MÖLLER (Germany)**

**D. BALDWIN (UK)**

11.00-11.30 **SO 0401** Cognition as a treatment target in obsessive compulsive disorders

**Naomi FINEBERG (UK)**

11.30-12.00 **SO 0402** The treatment of cognitive deficits in MDD

**David BALDWIN (UK)**

12.00-12.30 **SO 0403** Cognitive deficits in bipolar disorder

**Eduard VIETA (Spain)**

► Please note that a 5' discussion with the speaker is foreseen at the end of each presentation.





**12.30-13.30**

**Lunch**

**13.30-15.00**

## **SO 05 COGNITIVE DYSFUNCTION IN MAJOR DEPRESSIVE DISORDER - PATIENT PERCEPTIONS AND OBJECTIVE MEASURES**

Chair: **M. DORAISWAMY (USA)**

**13.30-13.35**

### **Welcome and introduction**

**13.35-14.00**

**SO 0501** Do patients and physicians have the same perceptions of cognitive symptoms in depression?

**Lawrence MARTIN (Canada)**

**14.00-14.25**

**SO 0502** Cognitive dysfunction in depressed patients: prevalence, risks and consequences

**Barbara SAHAKIAN (UK)**

**14.25-14.50**

**SO 0503** Assessment of cognitive dysfunction in depression

**Murali DORAISWAMY (USA)**

**14.50-15.00**

Discussion and closing remarks

**15.00-16.30**

## **SO 06 DEPRESSION, COGNITIVE AND NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: UNDERLYING NEUROBIOLOGY AND NOVEL LEADS FOR PHARMACOLOGICAL TREATMENT**

Chair: **S. KASPER (Austria)**

**J. LOFTUS (Monaco)**

**15.00-15.30**

**SO 0601** Do depressive cognitive and negative symptoms impact on outcome in schizophrenia?

**Hans-Juergen MOELLER (Germany)**

**15.30-16.00**

**SO 0602** Low doses of atypical antipsychotic drugs added to selective serotonin inhibitors produce a ketamine-like facilitation of prefrontal glutamatergic neurotransmission

**Torgny SVENSSON (Sweden)**

**16.00-16.30**

**SO 0603** Antidepressant drugs in schizophrenia and antipsychotic drugs in depression: basic and clinical perspective

**Siegfried KASPER (UK)**

► Please note that a 5' discussion with the speaker is foreseen at the end of each presentation.



## SCIENTIFIC PROGRAMME

**16.30-16.45**

**Coffee break**

**16.45-18.15 SO 07 ADHERENCE WITH TREATMENT**

Chair: **C. ALTAMURA (Italy)**

**H.P. VOLZ (Germany)**

**16.45-17.15 SO 0701** Compliance counselling in bipolar disorder  
**Carla TORRENT (Spain)**

**17.15-17.45 SO 0702** The treatment of cognitive deficits in MDD  
**Hans-Peter VOLZ (Germany)**

**17.45-18.15 SO 0703** Are any drug formulations inherently better for adherence?  
**Carlo ALTAMURA (Italy)**

► Please note that a 5' discussion with the speaker is foreseen at the end of each presentation.

**18.15-19.15 MEET THE EXPERT SESSION**

**Siegfried KASPER (Austria)**

**Stuart MONTGOMERY (UK)**



**FRIDAY, 22 November 2013**

## **09.00-10.30 SO 08 - THE REVISED DIAGNOSTIC CRITERIA OF MENTAL DISORDERS (DSM-5): BIPOLAR DISORDER IS BIPOLAR AGAIN – REVISITING THE CLASSICS**

Chair: ***M. DAVIDSON (Israel)***

**09.00-09.10 Welcome and introduction**

**SO 0801** DSM-5 – a critical appraisal  
***Michael DAVIDSON (Israel)***

**09.10-09.30 SO 0802** DSM-5 criteria for bipolar disorder: what has changed?  
***Alan SWANN (USA)***

**09.30-10.00 SO 0803** Implications for clinical management: State of the art treatment of mixed Mania - New data  
***Eduard VIETA (Spain)***

**10.00-10.30** Panel discussion Closing remarks

**10.30-11.00 Coffee break**

## **11.00-12.30 SO 09 - TREATMENT RESISTANT DEPRESSION**

Chair: ***S. MONTGOMERY (UK)***  
***S. KASPER (Austria)***

**11.00-11.30 SO 0901** Is resistant depression a signal for bipolar disorder?  
***Alessandro SERRETTI (Italy)***

**11.30-12.00 SO 0902** Favoured treatments for treatment resistant depression  
***Stuart A. MONTGOMERY (UK)***

**12.00-12.30 SO 0903** New finding in resistant depression - focus on anxiety comorbidity  
***Joseph ZOHAR (Israel)***

► Please note that a 5' discussion with the speaker is foreseen at the end of each presentation.



## SCIENTIFIC PROGRAMME

**12.30-13.30**

**Lunch**

**13.30-15.00**

### **SO 10 - TREATMENT OF MAJOR DEPRESSIVE DISORDER**

Chair: **E. ERIKSSON (Sweden)**

**A. SERRETTI (Italy)**

**13.30-14.00**

**SO 1001** The effect of comorbid anxiety on outcomes in major depressive disorder (MDD)

**Borwin BANDELOW (Germany)**

**14.00-14.30**

**SO 1002** Does being elderly alter response in major depressive disorder (MDD)?

**Cornelius KATONA (UK)**

**14.30-15.00**

**SO 1003** Cognitive behaviour therapy (CBT) in treatment resistant depression

**Elias ERIKSSON (Sweden)**

**15.00-16.30**

### **SO 11 - HOT TOPICS**

Chair: **B. BANDELOW (Germany)**

**C. KATONA (UK)**

**15.00-15.30**

**SO 1101** Behavioural addictions in adult ADHD

**Pierre-Michel LLORCA (France)**

**15.30-16.00**

**SO 1102** Biomarkers and prediction of response in major depressive disorder (MDD) – an update

**Dietmar WINKLER (Austria)**

**16.00-16.30**

**SO 1103** Neuropeptide Y and CRH in major depressive disorder (MDD)

**Aleksander A. MATHÉ (Sweden)**

**16.30-16.45**

**End of meeting**



## **P 01. Presentation of body dysmorphic disorder in dermatology**

Amir, A ElKhalifa Mufadel<sup>1</sup>; Ossama T. Osman<sup>2</sup>

<sup>1</sup>AlAin Hospital, Behavioural Science Institute, Community Mental Health Services, AlAin, United Arab Emirates; <sup>2</sup>Faculty of Medicine and Health Sciences, United Arab Emirates University, PO Box 17666, AlAin, United Arab Emirates, AlAin, United Arab Emirates

## **P 02. A population pharmacokinetic (PK)-pharmacodynamic (PD)meta analysis of vortioxetine in patients with major depressive disorder (MDD)**

Johan Areberg<sup>1</sup>; Serena Chan<sup>2</sup>; Mayid Vakilynejad<sup>2</sup>; Grace Chen<sup>2</sup>; Henrik Loft<sup>1</sup>; Atul Mahableshwarkar<sup>2</sup>; Himanshu Naik<sup>2</sup>

<sup>1</sup>H. Lundbeck A/S, Valby, Denmark; <sup>2</sup>Takeda Global Research and Development Center, Deerfield, USA

## **P 03. A course of the illness and clinical characteristics of mixed states in bipolar mania**

Won-Myong Bahk<sup>1</sup>; Young Sup Woo<sup>1</sup>; Hoo Rim Song<sup>1</sup>; Hee-Ryung Wang<sup>1</sup>; Moon Doo Kim<sup>2</sup>; In Hee Shim<sup>1</sup>

<sup>1</sup>Department of Psychiatry, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea; <sup>2</sup>Department of Psychiatry, School of Medicine, Jeju National University, Jeju, South Korea

## **P 04. Is it useful to use the Korean version of the mood disorder questionnaire for assessing bipolar spectrum disorder among Korean college students?**

Won-Myong Bahk<sup>1</sup>; Moon Doo Kim<sup>2</sup>; Jung Goo Lee<sup>3</sup>; Jeong-Seok Seo<sup>4</sup>; Seung-Hee Won<sup>5</sup>; Young Sup Woo<sup>1</sup>; Seung Oh Bae<sup>6</sup>; Young Joon Kwon<sup>7</sup>; Won Kim<sup>8</sup>; Kyung Joon Min<sup>9</sup>; Duk-In Jon<sup>10</sup>; Young Chul Shin<sup>11</sup>; Yoon Bo-Hyun<sup>12</sup>

<sup>1</sup>Department of Psychiatry, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea; <sup>2</sup>Department of Psychiatry, School of Medicine, Jeju National University, Jeju, South Korea; <sup>3</sup>Department of Psychiatry, College of Medicine, Inje University Haeundae Paik Hospital and Paik Institute for Clinical Research, Busan, South Korea; <sup>4</sup>Department of Psychiatry, College of Medicine, Konkuk University, Chungju, South Korea; <sup>5</sup>Department of Psychiatry, College of Medicine, Kyungpook National University, Daegu, South Korea; <sup>6</sup>Hangang Mental Clinic, Kimpo, South Korea; <sup>7</sup>Department of Psychiatry, College of Medicine, Soonchunhyang University, Chunan, South Korea; <sup>8</sup>Department of Psychiatry, College of Medicine, Inje University, Seoul, South Korea; <sup>9</sup>Department of Psychiatry, College of Medicine, Chung-Ang University, Seoul, South Korea; <sup>10</sup>Department of Psychiatry, College of Medicine, Hallym University, Anyang, South Korea; <sup>11</sup>Department of Psychiatry, Kangbuk Samsung Hospital, School of Medicine, Sungkyunkwan University, Seoul, South Korea; <sup>12</sup>Naju National Hospital, Naju, South Korea



### **P 05. Korean medication algorithm for depressive disorder: comparisons with other treatment guidelines**

Won-Myong Bahk<sup>1</sup>; Hee Ryung Wang<sup>1</sup>; Young-Min Park<sup>2</sup>; Hwang Bin Lee<sup>3</sup>; Hoo Rim Song<sup>1</sup>; Jong-Hyun Jeong<sup>4</sup>; Jeong Seok Seo<sup>5</sup>; Eun-Sung Lim<sup>6</sup>; Jeong-Wan Hong<sup>7</sup>; Won Kim<sup>8</sup>; Duk-In Jon<sup>9</sup>; Jin-Pyo Hong<sup>10</sup>; Young Sup Woo<sup>1</sup>; Kyung Joon Min<sup>11</sup>

<sup>1</sup>Department of Psychiatry, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea; <sup>2</sup>Department of Psychiatry, Ilsan Paik Hospital, College of Medicine, Inje University, Goyang, South Korea; <sup>3</sup>Department of Psychiatry, Seoul National Hospital, Seoul, South Korea; <sup>4</sup>Department of Psychiatry, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, South Korea; <sup>5</sup>Department of Psychiatry, School of Medicine, Konkuk University, Chungju, South Korea; <sup>6</sup>Shinsegae Hospital, Kimje, South Korea; <sup>7</sup>Namwon Sungil Mental Hospital, Namwon, South Korea; <sup>8</sup>Department of Psychiatry, Seoul Paik Hospital, College of Medicine, Inje University/Stress Research Institute, Inje University, Seoul, South Korea; <sup>9</sup>Department of Psychiatry, College of Medicine, Hallym University, Anyang, South Korea; <sup>10</sup>Department of Psychiatry, College of Medicine, Ulsan University, Seoul, South Korea; <sup>11</sup>Department of Psychiatry, College of Medicine, Chung-Ang University, Seoul, South Korea

### **P 06. Mixed-state bipolar I and II depression: Time to remission and clinical characteristics**

Won-Myong Bahk<sup>1</sup>; Young Sup Woo<sup>1</sup>; Hoo Rim Song<sup>1</sup>; Hee-Ryung Wang<sup>1</sup>; Kyung Joon Min<sup>2</sup>; Tae-Youn Jun<sup>1</sup>; In Hee Shim<sup>1</sup>

<sup>1</sup>Department of Psychiatry, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea; <sup>2</sup>Department of Psychiatry, College of Medicine, Chung-Ang University, Seoul, South Korea

### **P 07. The differences in the clinical characteristics and treatment pattern between bipolar disorder patients with and without psychiatric comorbidity**

Won-Myong Bahk<sup>1</sup>; Hoo Rim Song<sup>1</sup>; Young Sup Woo<sup>1</sup>; Tae-Youn Jun<sup>1</sup>; Kwang-Soo Kim<sup>1</sup>; Hee-Ryung Wang<sup>1</sup>

<sup>1</sup>Department of Psychiatry, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea

### **P 08. The differences in the clinical characteristics and treatment pattern between major depressive disorder patients with and without psychiatric comorbidity**

Won-Myong Bahk<sup>1</sup>; Hoo Rim Song<sup>1</sup>; Young Sup Woo<sup>1</sup>; Tae-Youn Jun<sup>1</sup>; Kwang-Soo Kim<sup>1</sup>; Hee-Ryung Wang<sup>1</sup>

<sup>1</sup>Department of Psychiatry, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea



## **P 09. The safety and tolerability of vortioxetine (Lu AA21004) in the treatment of adults with major depressive disorder (MDD): A pooled analysis**

David S. Baldwin<sup>1</sup>; Michael Serenko<sup>2</sup>; William Palo<sup>2</sup>; Søren Lophaven<sup>3</sup>; Jørgen Matz<sup>3</sup>

<sup>1</sup>Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, United Kingdom; <sup>2</sup>Takeda Development Center Americas, Deerfield IL, USA; <sup>3</sup>H. Lundbeck A/S, Copenhagen, Denmark

## **P 10. The prevalence of bipolar spectrum disorder in the Korean college students according to the K-MDQ**

Yoon Bo-Hyun<sup>1</sup>; Kim Moon Doo<sup>2</sup>; Lee Jung Goo<sup>3</sup>; Seo Jeong-Seok<sup>4</sup>; Won Seung-Hee<sup>5</sup>; Woo Young Sup<sup>6</sup>; Lee Kwanghun<sup>7</sup>; Kim Won<sup>8</sup>; Min Kyung Joon<sup>9</sup>; Jon Duk-In<sup>10</sup>; Shin Young Chul<sup>11</sup>; Bahk Won-Myong<sup>6</sup>; Bae Seung Oh<sup>12</sup>

<sup>1</sup>Naju National Hospital, Naju, South Korea; <sup>2</sup>Department of Psychiatry, School of Medicine, Jeju National University, Jeju, South Korea; <sup>3</sup>Department of Psychiatry, College of Medicine, Inje University Haeundae Paik Hospital and Paik Institute for Clinical Research, Busan, South Korea; <sup>4</sup>Department of Psychiatry, College of Medicine, Konkuk University, Chungju, South Korea; <sup>5</sup>Department of Psychiatry, College of Medicine, Kyungpook National University, Daegu, South Korea; <sup>6</sup>Department of Psychiatry, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea; <sup>7</sup>Department of Psychiatry, College of Medicine, Dongguk University, Gyeongju, South Korea; <sup>8</sup>Department of Psychiatry, College of Medicine, Inje University, Seoul, South Korea; <sup>9</sup>Department of Psychiatry, College of Medicine, Chung-Ang University, Seoul, South Korea; <sup>10</sup>Department of Psychiatry, College of Medicine, Hallym University, Anyang, South Korea; <sup>11</sup>Department of Psychiatry, Kangbuk Samsung Hospital, School of Medicine, Sungkyunkwan University, Seoul, South Korea; <sup>12</sup>Hangang Mental Clinic, Kimpo, South Korea

## **P 11. Effect of polymorphisms in tryptophan hydroxylase 2 Gene on suicide risk in Korean patients with major depressive disorder**

Kim Chan-Hyung<sup>1</sup>; Nam Yoon-Young<sup>2</sup>

<sup>1</sup>Dept. of Psychiatry, Yonsei University College of Medicine, Seoul, South Korea; <sup>2</sup>Dept. of Planning & Public relations, Seoul National Hospital, Seoul, South Korea

## **P 12. Generalized poststroke anxiety disorders: clinical and radiological correlation**

Lili Chinchaladze; Nino Lobjanidze; Marina Janelidze; Nana Kvirkvelia; Ketevan Esartia; Sopio Kapanidze; Nino Akiashvili; Tea Maisuradze  
Khechinashvili Medical University Hospital, Tbilisi, Georgia



**P 13. Efficacy and tolerability of escitalopram and pregabalin in patients with generalized anxious disorder (GAD)**

M.Cvjetkovi -Bošnjak, B.Soldatović-Staji , M.Latas, A.Nedić, B. Sakić, S.Babovic  
*Psychiatric Clinic,KCV, Novi Sad,Serbia*

**P 14. Survey about headache in patients with obstructive sleep night apneas and anxiety disorders**

Domenico Di Nicola<sup>1</sup>; Antonio Lera<sup>2</sup>

<sup>1</sup>*Università degli Studi de L'Aquila, Scuola di Specializzazione in Psichiatria, L'Aquila, Italy;*

<sup>2</sup>*U.O. Psichiatria a Direzione Universitaria O.C. Giulianova, ASL Teramo, Teramo, Italy*

**P 15. TINDER: a new strategy in disorder of sleep-wakefulness sphere associated with mild depression**

Domenico Di Nicola<sup>1</sup>; Antonio Lera<sup>2</sup>

<sup>1</sup>*University of L'Aquila, School di Specialization of Psichiatria, L'Aquila, Italy;* <sup>2</sup>*DSM TERAMO-Giulianova Civil Hospital Neuropsychiatry Unit of Psychiatry to Academic Direction, Alessandro Rossi, Teramo, Italy*

**P 16. Manic vs mixed; the evaluation of anxiety, depression and global assessment of functioning in bipolar patients**

Parisa Divsalar<sup>1,2</sup>

<sup>1</sup>*Bam University of Medical Sceince, Bam, Iran;* <sup>2</sup>*Priory Cheadle Royal Hospital, Manchester, United Kingdom*

**P 17. Predictors and consequences of post-stroke depression in a sample of Egyptian patients**

Heba Essawy<sup>1</sup>; Safia Effat<sup>2</sup>; Mona Mansour<sup>3</sup>; Mona El Sheik<sup>4</sup>; Howeida Abd Alaa<sup>5</sup>

<sup>1</sup>*Institute of Psychiatry, Cairo, Egypt;* <sup>2</sup>*Institute of Psychiatry, Cairo, Egypt;* <sup>3</sup>*Institute of Psychiatry, Cairo, Egypt;* <sup>4</sup>*Institute of Psychiatry, Cairo, Egypt;* <sup>5</sup>*Institute of Psychiatry, Cairo, Egypt*

**P 18. Dialectical behavior therapy in bipolar disorder: clinical applications in outpatient population at Tripler Army Medical Center- a proposed treatment**

Francisco Fletes; John Daula; Elizabeth Guinto Kwak

*Tripler Army Medical Center, Honolulu, USA*





**P 19. Transcranial Light Alters the Expression of Brain Enkephalopsin and Plasma Monoamine Concentration in the Mouse**

Antti Flyktman<sup>1</sup>; Satu Mänttari<sup>1</sup>; Juuso Nissilä<sup>1</sup>; Markku Timonen<sup>1</sup>; Seppo Saarela<sup>1</sup>

<sup>1</sup>University of Oulu, Oulu, Finland

**P 20. Eye movement desensitization reprocessing, posttraumatic stress disorder, and trauma: a review of randomized controlled trials with children and adolescents**

Laura Greyber<sup>1,2</sup>; Catherine Dulmus<sup>1,2</sup>; Maria Cristalli<sup>1,2</sup>

<sup>1</sup>Hillside Family of Agencies, Rochester, USA; <sup>2</sup>University at Buffalo, Buffalo, USA

**P 21. Age-dependent memory impairment is improved by vortioxetine in old female mice**

Maria Gulinello<sup>1</sup>; Yan Li<sup>2</sup>; Connie Sánchez<sup>2</sup>

<sup>1</sup>Behavioral Core Facility, Neuroscience Dept, Albert Einstein College of Medicine, Bronx, USA; <sup>2</sup>External Sourcing and Scientific Excellence, Lundbeck Research USA, Paramus, USA

**P 22. The prevalence of depression among resident doctors working in a teaching hospital in Karachi, Pakistan**

Sobia Haqqi

Ziauddin University, Karachi, Pakistan

**P 23. The questioning of the efficacy of antidepressants is based on the use of an inappropriate measure of improvement**

Fredrik Hieronymus; Johan Fredrik Emilsson; Elias Eriksson

Sahlgrenska Academy, Gothenburg, Sweden

**P 24. Childhood trauma and adult interpersonal relationship problems in patients with depression and anxiety disorder**

Hyu Jung Huh; Jeong-Ho Chae

Department of Psychiatry, Seoul St. Mary's Hospital, The Catholic University of Korea, College of Medicine, Seoul, South Korea

**P 25. An auditory time reproduction task in bipolar disorder**

Sohn Inki

Keyo Hospital, Uiwang City, South Korea



**P 26. Transcranial light exposure acutely alleviate anxiety symptoms in moderately depressed participants - A randomized, sham-controlled, double-blind trial**

Heidi Jurvelin<sup>1,2,3</sup>, Markku Timonen<sup>1</sup>, Johanna Lammi<sup>4</sup>, Jari Jokelainen<sup>1,5</sup>, Melanie Rueger<sup>3</sup>, Timo Takala<sup>3</sup>

<sup>1</sup>University of Oulu, Institute of Health Sciences, Box 5000, 90014 Oulu, Finland

<sup>2</sup>University of Oulu, Institute of Clinical Medicine, Department of Psychiatry, Box 5000, 90014 Oulu, Finland; <sup>3</sup>Valkee Ltd, Elekroniikkatie<sup>4</sup>, 90590 Oulu, Finland <sup>4</sup>University of Oulu, Department of Biology, P.O. Box 3000, FIN-90014 University of Oulu, Finland;

<sup>5</sup>Oulu University Hospital, Unit of General Practice, 90029 Oulu, Finland

**P 27. Autonomic panic disorders after stroke**

Sopio Kapianidze; M. Janelidze; N. Kvirkvelia; N. Lobjanidze; M. Kapianidze  
S.Khechinashvili Medical University Hospital, Tbilisi, Georgia

**P 28. Hypertension and multiple brain damage integrity in late-life depression**

Sopio Kapianidze; M. Janelidze; N. Kvirkvelia; K. Esartia; N. Lobjanidze;  
N. Akiashvili; L. Chinchaladze; T. Maisuradze; S. Khechinashvili Medical University Hospital,  
Tbilisi, Georgia

**P 29. Use of antipsychotics in management of depression, anxiety disorder with depression and OCD**

Kim Wei Lim; Yee Ming Mok  
Institute of Mental Health, Singapore, Singapore

**P 30. Relative frequency of unipolar mania among hospitalized patients and its associate features: a multicenter study in Iran**

Fatemeh Khodaeifar<sup>1</sup>; Shahrokh Sardar Gudarzi<sup>2</sup>; Alireza Ghaffarinejad<sup>3</sup>; Maryam Javanbakht<sup>4</sup>; Venus Mahmoodi<sup>5</sup>; Alireza Mirghiasi<sup>6</sup>

<sup>1</sup>Behavioral Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Tehran, Iran; <sup>2</sup>Melbourne Health, Melbourne VIC, Melbourne, Australia;

<sup>3</sup>Department of Psychiatry, Kerman University of Medical Science, Kerman, Iran, Kerman, Iran; <sup>4</sup>Department of Psychiatry, Mashhad Branch, Islamic Azad University, Mashhad, Iran, Mashhad, Iran; <sup>5</sup>Behavioral Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Tehran, Iran; <sup>6</sup>Modarres Hospital, Esfahan, Iran, Esfahan, Iran

**P 31. Depression and suicidal ideation in community dwelling elderly**

Kwanghun Lee  
Dongguk University Hospital, Gyeongju, South Korea



**P 32. Modulation of prefrontal-cingulate connectivity in affective processing of ostracized children**

Kyoung-Uk Lee<sup>1</sup>; Chang-Hyun Park<sup>2</sup>; Hyun-Seung Lee<sup>3</sup>; Ji-Eun Lee<sup>3</sup>; Young-Hoon Kim<sup>3</sup>; Ki-Tae Kim<sup>4</sup>; Young-Joo Kim<sup>4</sup>

<sup>1</sup>Department of Psychiatry, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, South Korea; <sup>2</sup>Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, London, United Kingdom; <sup>3</sup>Department of Pediatrics, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, South Korea; <sup>4</sup>Department of Radiology, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, South Korea

**P 33. Behavioural effects of acute agomelatine doses in male mice social interaction model**

Alena Machalova<sup>1,2</sup>; Alexandra Sulcova<sup>2</sup>

<sup>1</sup>Department of Pharmacology, Faculty of Medicine, Masaryk university Brno, Brno, Czech Rep; <sup>2</sup>CEITEC (Central European Institute of Technology), Masaryk University Brno, Brno, Czech Republic

**P 34. Differences in frontal cortex vulnerability due to antipsychotics used in treatment of depressive disorder (animal model)**

Ileana Marinescu; Ion Udristoiu; Laurentiu Mogoanta; Tudor Udristoiu  
University of Medicine and Pharmacy of Craiova, Craiova, Romania

**P 35. Depression in first episode schizophrenia patients – data from Romanian cohort of EUFEST Study**

Valentin Petre Matei<sup>1,2</sup>; Alexandra Ioana Mihailescu<sup>1,2</sup>; Dorina Valerica Sima<sup>1</sup>

<sup>1</sup>Hospital of Psychiatry "Prof dr Al. Obregia", Bucharest, Romania; <sup>2</sup>University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania

**P 36. Social class and depression risk**

Valentin Matei; Dan Prelipceanu

Al Obregia Psychiatric Hospital, Bucharest, Romania

**P 37. Characteristics of elderly suicide attempters in Korea; distinction between "Young-old" vs "Old-old"**

Min-Hyuk Kim; Hyun-Jin Noh

Department of Psychiatry, Yonsei University Wonju College of Medicine, Wonju, South Korea



**P 38. An integrated model to improve access to psychiatric treatment in homebound elderly with depression**

Mirnova Ceide; Janice Korenblatt

*Montefiore Medical Center, Bronx, NY, USA*

**P 39. A study of phenomenology of anxiety disorders in children and adolescents from India**

Satyakam Mohapatra

*SCB Medical College, Cuttack, India*

**P 40. First year depression data from a treatment resistant clinic**

Mok Yee Ming

*Head, Mood Disorder Unit - Institute of Mental Health - Singapore*

**P 41. Lithium intoxication within normal therapeutic blood level: a case report**

Moon-Doo Kim<sup>1</sup>; Sangkeun Chung<sup>2</sup>; Bo-Hyun Yoon<sup>3</sup>; Young-Joon Kwon<sup>4</sup>; Sang-Yeol Lee<sup>5</sup>; Kyung-Joon Min<sup>6</sup>; Won-Myong Bahk<sup>7</sup>

<sup>1</sup>Jeju National University Hospital, Jeju, South Korea; <sup>2</sup>Chonbuk University Hospital, Jeonju, South Korea; <sup>3</sup>Naju National Hospital, Naju, South Korea; <sup>4</sup>Soonchunhyang University Cheonan Hospital, Cheonan, South Korea; <sup>5</sup>Wonkwang University Hospital, Iksan, South Korea; <sup>6</sup>Chungang University Hospital, Seoul, South Korea; <sup>7</sup>Catholic University Yeouido St. Mary's Hospital, Seoul, South Korea

**P 42. Treatment of neuroleptic malignant syndrome in child and adolescent: a case report**

Moon-Doo Kim<sup>1</sup>; Sangkeun Chung<sup>2</sup>; Bo-Hyun Yoon<sup>3</sup>; Young-Joon Kwon<sup>4</sup>; Sang-Yeol Lee<sup>5</sup>; Kyung-Joon Min<sup>6</sup>; Won-Myong Bahk<sup>7</sup>

<sup>1</sup>Jeju National University Hospital, Jeju, South Korea; <sup>2</sup>Chonbuk University Hospital, Jeonju, South Korea; <sup>3</sup>Naju National Hospital, Naju, South Korea; <sup>4</sup>Soonchunhyang University Cheonan Hospital, Cheonan, South Korea; <sup>5</sup>Wonkwang University Hospital, Iksan, South Korea; <sup>6</sup>Chungang University Hospital, Seoul, South Korea; <sup>7</sup>Catholic University Yeouido St. Mary's Hospital, Seoul, South Korea

**P 43. Depression in Iraq sociodemographic study**

Jameel Muslim

*Psychiatry, Baghdad, Iraq*



## **P 44. Frequency and impact of pain symptoms in patients with depression in Taiwan**

Diego Novick<sup>1</sup>; William Montgomery<sup>2</sup>; Maria Victoria Moneta<sup>3</sup>; Xiaomei Peng<sup>4</sup>; Roberto Brugnoli<sup>5</sup>; Joyce Yeh<sup>6</sup>; Josep Maria Haro<sup>3</sup>

<sup>1</sup>Eli Lilly and Company, Windlesham, United Kingdom; <sup>2</sup>Eli Lilly Australia Pty Ltd, Sydney, Australia; <sup>3</sup>Parc Sanitari Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain; <sup>4</sup>Eli Lilly and Company, Indianapolis, USA; <sup>5</sup>University of Rome 'Sapienza', Rome, Italy; <sup>6</sup>Eli Lilly and Company, Taipei, Taiwan

## **P 45. Frequency and impact of pain symptoms in patients with depression in Malaysia**

Diego Novick<sup>1</sup>; William Montgomery<sup>2</sup>; Maria Victoria Moneta<sup>3</sup>; Xiaomei Peng<sup>4</sup>; Roberto Brugnoli<sup>5</sup>; Rodney Filemon<sup>6</sup>; Josep Maria Haro<sup>3</sup>

<sup>1</sup>Eli Lilly and Company, Windlesham, United Kingdom; <sup>2</sup>Eli Lilly Australia Pty Ltd, Sydney, Australia; <sup>3</sup>Parc Sanitari Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain; <sup>4</sup>Eli Lilly and Company, Indianapolis, USA; <sup>5</sup>University of Rome 'Sapienza', Rome, Italy; <sup>6</sup>Eli Lilly and Company, Manila, Philippines

## **P 46. Treatment effectiveness for patients major depressive disorder treated with either duloxetine or selective serotonin reuptake inhibitors in Middle East**

Diego Novick<sup>1</sup>; Jihyung Hong<sup>1</sup>; William Montgomery<sup>2</sup>; Hector Duenas<sup>3</sup>; Magdy Gado<sup>4</sup>; Josep Maria Haro<sup>5</sup>

<sup>1</sup>Eli Lilly and Company, Windlesham, United Kingdom; <sup>2</sup>Eli Lilly Australia Pty Ltd, Sydney, Australia; <sup>3</sup>Eli Lilly and Company, Mexico, Mexico; <sup>4</sup>Eli Lilly and Company, Riyadh, Saudi Arabia; <sup>5</sup>Parc Sanitari Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain

## **P 47. Impact of anxiety symptoms on outcomes of depression. A study in patients from Asia**

Diego Novick<sup>1</sup>; William Montgomery<sup>2</sup>; Jaume Aguado<sup>3</sup>; Xiaomei Peng<sup>4</sup>; Roberto Brugnoli<sup>5</sup>; Josep Maria Haro<sup>3</sup>

<sup>1</sup>Eli Lilly and Company, Windlesham, United Kingdom; <sup>2</sup>Eli Lilly Australia Pty Ltd, Sydney, Australia; <sup>3</sup>Parc Sanitari Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain; <sup>4</sup>Eli Lilly and Company, Indianapolis, USA; <sup>5</sup>University of Rome 'Sapienza', Rome, Italy



### **P 48. Adverse cutaneous effects of mood stabilizers**

Ossama T. Osman<sup>1</sup>; Mufaddel Amir<sup>2</sup>

<sup>1</sup>Faculty of Medicine and Health Sciences, United Arab Emirates University, PO Box 17666, AlAin, United Arab Emirates, AlAin, United Arab Emirates; <sup>2</sup>AlAin Hospital, Behavioural Science Institute, Community Mental Health Service, AlAin, United Arab Emirates

### **P 49. Trauma informed care survey of psychiatrists and primary care physicians in the Middle East**

Ossama Osman<sup>1</sup>; Richard Mollica<sup>2</sup>; Laeth Nasir<sup>3</sup>; Jawad Hashim<sup>1</sup>; James Lavelle<sup>2</sup>; Noor Amawi<sup>2</sup>

<sup>1</sup>College of Medicine - United Arab Emirates University, AlAin, United Arab Emirates;

<sup>2</sup>Harvard Program on Refugee Trauma, Boston, USA; <sup>3</sup>Creighton University School of Medicine, Omaha, USA

### **P 50. Prevalence and sociodemographic correlates of premenstrual dysphoric disorder symptoms in the Gulf city of AlAin**

Ossama Osman<sup>1</sup>; Sufyan Sabri<sup>1</sup>; Amal Shamsan<sup>1</sup>; Daa Rizk<sup>2</sup>; Hanan Alraesi<sup>1</sup>

<sup>1</sup>College of Medicine and Health Sciences- United Arab Emirates University, AlAin, United Arab Emirates; <sup>2</sup>Faculty of Medicine- Ain Shams University, Cairo, Egypt

### **P 51. Polarity index in bipolar disorder maintenance treatment: a naturalistic study**

Dina Popovic; Carla Torrent; Eduard Vieta

Bipolar Disorders Program, Hospital Clinic, University of Barcelona, Barcelona, Spain

### **P 52. Trait impulsivity and clinical characteristics in bipolar disorder**

Philip Rankin<sup>1</sup>; Katherine Gordon-Smith<sup>1</sup>; Liz Forty<sup>2</sup>; Ian Jones<sup>2</sup>; Nick Craddock<sup>2</sup>;

Lisa Jones<sup>1</sup>

<sup>1</sup>University of Birmingham, Birmingham, United Kingdom; <sup>2</sup>University of Cardiff, Cardiff, United Kingdom

### **P 53. The effect of self esteem and social support on suicidal ideation among elderly in a city of Korea: focused on the mediating effect of depressive symptoms**

Lee Sang Yeol<sup>1</sup>; Jeongwan Hong<sup>2</sup>

<sup>1</sup>Department of Psychiatry, Wonkwang University School of Medicine and Hospital, Iksan, South Korea; <sup>2</sup>Namwon Sungil Hospital, Namwon, South Korea

### **P 54. Prevalence of depression and correlated psychosocial factors of married immigrant women in a city of Republic of Korea**

Lee Sang Yeol<sup>1</sup>; Chung Sang-Keun<sup>2</sup>

<sup>1</sup>Department of Psychiatry, Wonkwang University School of Medicine and Hospital, Iksan, South Korea; <sup>2</sup>Department of Psychiatry, Chonbuk National University Medical School, Jeonju, South Korea



**P 55. Diagnosis and treatment of an adolescent with Tourett**

Se-Hoon Shim<sup>1</sup>; Sang-Keun Chung<sup>2</sup>; Kyung-Joon Min<sup>3</sup>; Jeong-Wan Hong<sup>4</sup>; Young-Joon Kwon<sup>1</sup>

<sup>1</sup>Soonchunhyang University Cheonan Hospital, Cheonan, South Korea; <sup>2</sup>Chonbuk National University Hospital, Jeonju, South Korea; <sup>3</sup>Chungang University Hospital, Seoul, South Korea; <sup>4</sup>Namwon Sungil Hospital, Namwon, South Korea

**P 56. Mental disorders in offspring of parents with bipolar disorders**

Se-hoon Shim<sup>1</sup>; Sang-Keun Chung<sup>2</sup>; Kyung-Joon Min<sup>3</sup>; Jeong-Wan Hong<sup>4</sup>; Young-Joon Kwon<sup>1</sup>

<sup>1</sup>Soonchunhyang University Cheonan Hospital, Cheonan, South Korea; <sup>2</sup>Chonbuk National University Hospital, Jeonju, South Korea; <sup>3</sup>Chungang University Hospital, Seoul, South Korea; <sup>4</sup>Namwon Sungil Hospital, Namwon, South Korea

**P 57. Psychotic symptoms in a sample of Albanian immigrants – correlation between sociodemographic factors and psychosys**

Elga Spaho<sup>1</sup>, Valmira Skendi<sup>1</sup>, Anila Hashorva<sup>1</sup>, Valbona Alikaj<sup>2</sup>

<sup>1</sup>University Hospital Center „Mother Teresa“, Tirana, Albania; <sup>2</sup>Faculty of Medicine, University Hospital Center, Mother Teresa“, Tirana, Abania

**P 58. Typical emotional states of adolescents with serious progress of a chronic disease**

Tatiana Sviridova<sup>1</sup>; Svetlana Lazurenko<sup>2</sup>; Leila Namazova-Baranova<sup>3</sup>

<sup>1</sup>Medical psychologist of “ Scientific Center of Children’s Health” of the Russian Academy of Medical Sciences (RAMS),, Moscow, Russia; <sup>2</sup>Head of the Laboratory of Special Psychology and Correctional Training of “ Scientific Center of Children’s Health” of the RAMS, Moscow, Russia; <sup>3</sup>Director of the Research Institute of Preventive Pediatrics and Recreational Corresponding Member of the RAMS, Professor, Doctor of Medical Sciences, Deputy Head of “ Scientific Center of Children’s Health” of the RAMS,, Moscow, Russia

**P 59. Psychosocial dimensions of chronic rheumatoid diseases**

Andreea Silvana Szalontay<sup>1,3</sup>; Corina Dima Cozma<sup>2</sup>; Manuela Paraschiv<sup>3</sup>; Raluca Iustina Vitalaru<sup>3</sup>; Elena Rezus<sup>4</sup>

<sup>1</sup>Department of Psychiatry University of Medicine and Pharmacy "Grigore T. Popa, Iasi, Iasi, Romania; <sup>2</sup>Department of Internal Medicine, University of Medicine and Pharmacy "Grigore T. Popa", Iasi, Iasi, Romania; <sup>3</sup>Clinical Hospital of Psychiatry „Socola” Iasi, Iasi, Romania; <sup>4</sup>Department of Rheumatology, University of Medicine and Pharmacy "Grigore T. Popa", Iasi, Iasi, Romania



### **P 60. Association between symptoms of posttraumatic stress disorder and blood pressure in the elderly**

Tae Yong Kim; Yu Jin Bang; Suk Hoon Kang; Hae Gyung Chung; Jin Hee Choi; Hyung Seok So

*VHS Medical Center, Seoul, South Korea*

### **P 61. The efficacy and safety of milnacipran in patients with major depressive disorder following initial treatment failure with a selective serotonin reuptake inhibitor: a pragmatic 24-week, multicentre, open-label study**

Hashimoto Tasuku<sup>1</sup>; Yasunori Oda<sup>1</sup>; Tadashi Hasegawa<sup>2</sup>; Nobuhisa Kanahara<sup>3</sup>; Tsuyoshi Sasaki<sup>2,4</sup>; Hideki Komatsu<sup>2,4</sup>; Junpei Takahashi<sup>4</sup>; Takahiro Oiwa<sup>5</sup>; Kiyoshi Sakashita<sup>5</sup>; Tamaki Ishima<sup>7</sup>; Naoko Takase<sup>5</sup>; Shuichi Kikuchi<sup>6</sup>; Yoshimoto Sekine<sup>8</sup>; Kenji Hashimoto<sup>7</sup>; Masaomi Lyo<sup>1</sup>

<sup>1</sup>Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan;

<sup>2</sup>Department of Psychiatry, Chiba University Hospital, Chiba, Japan; <sup>3</sup>Division of Medical Treatment and Rehabilitation, Chiba University Center for Forensic Mental Health, Chiba, Japan; <sup>4</sup>Choshi Kokoro Clinic, Choshi, Japan; <sup>5</sup>Mobara Shinkeika Hospital, Mobara, Japan;

<sup>6</sup>Sodegaura Satsukidai Hospital, Sodegaura, Japan; <sup>7</sup>Division of Clinical Neuroscience Chiba University Center for Forensic Mental Health, Chiba, Japan; <sup>8</sup>Ishigooka Hospital, Chiba, Japan

### **P 62. NIDS (Neuroleptic-Induced Deficit Syndrome) in bipolar disorder with psychosis: three cases of prolonged treatment course**

Satoshi Ueda<sup>1</sup>; Ataru Omori<sup>1</sup>; Hajime Fukuta<sup>1,2</sup>; Takeshi Kobayashi<sup>1,2</sup>; Takeshi Sakayori<sup>1</sup>; Kousuke Ishizaka<sup>1,3</sup>; Tomoyuki Saijo<sup>1,4</sup>; Masahiro Yamamoto<sup>1</sup>; Yoshiro Okubo<sup>1</sup>

<sup>1</sup>Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan; <sup>2</sup>Kurumegaoka Hospital, Tokyo, Japan; <sup>3</sup>Asai Hospital, Chiba, Japan; <sup>4</sup>Saijo Clinic, Tokyo, Japan

### **P 63. Efficacy of asenapine in manic episodes with depressive symptoms: a review of post-hoc analyses**

Allan Young<sup>1</sup>; Jonas Eberhard<sup>1,2</sup>; Emmanuelle Weiller<sup>2</sup>

<sup>1</sup>Institute of Psychiatry, King's College London; <sup>2</sup>H.Lundbeck A/S, Copenhagen, Denmark

### **P 64. Effects of tianeptine on mTOR signaling in rat hippocampal neurons**

Young Hoon Kim<sup>1,2</sup>; Jung Goo Lee<sup>1,2</sup>; Mi Kyoung Seo<sup>2</sup>; Sung Woo Park<sup>2</sup>; Hye Yeon Cho<sup>2</sup>; Chan Hong Lee<sup>2</sup>

<sup>1</sup>Department of Psychiatry, Inje University Haeundae Paik Hospital, Busan, South Korea;

<sup>2</sup>Inje University Paik Institute for Clinical Research, Busan, South Korea





**P 65. Diagnostic stability in major depressive disorder according to DSM-IV: 4-year retrospective study in a university hospital**

Young Sup Woo<sup>1</sup>; Hyun-Joon Kim<sup>1</sup>; Tae-Yeon Hwang<sup>2</sup>; Bahk Won-Myong<sup>1</sup>

<sup>1</sup>Department of Psychiatry, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea; <sup>2</sup>WHO Collaborating Center for Psychosocial Rehabilitation and Community Mental Health, Yongin Mental Hospital, Yongin, South Korea

**P 66. Differentiating between bipolar disorder types I and II: focusing on depressive symptoms**

Young Sup Woo<sup>1</sup>; In-Woo Kim<sup>1</sup>; Tae-Youn Jun<sup>1</sup>; Kwang-Soo Kim<sup>1</sup>; Tae-Yeon Hwang<sup>2</sup>; Bahk Won-Myong<sup>1</sup>

<sup>1</sup>Department of Psychiatry, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea; <sup>2</sup>WHO Collaborating Center for Psychosocial Rehabilitation and Community Mental Health, Yongin Mental Hospital, Yongin, South Korea

**P 67. Duloxetine-induced burning paresthesia**

Young Sup Woo; Bahk Won-Myong

Department of Psychiatry, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea

**P 68. Clinical predictors of family accommodation in obsessive-compulsive disorder: a study from India**

Anish Cherian<sup>1,2</sup>; Dhanasekara Pandian<sup>2</sup>; Suresh Badamath<sup>2</sup>; Thennarasu Kandavel<sup>2</sup>; YCJ Reddy<sup>2</sup>

<sup>1</sup>K. S. Hegde Medical Academy, Mangalore, India; <sup>2</sup>National Institute of Mental Health & Bangalore, India

**P 69. Perceived experiences are modulated by interplay between stress hormones and monoamines in cortex; lessons from insula-dependent arousal-induced taste neophobia**

Moraga-Amaro R<sup>1</sup>, Diaz-Galarce R<sup>1</sup>, Rojas S<sup>1</sup>, Roozendaal B<sup>2</sup>, Stehberg J<sup>1</sup>

<sup>1</sup>Laboratorio de Neurobiología, Centro de Investigaciones Biomédicas, Universidad Andrés Bello, <sup>2</sup>Department of Cognitive Neuroscience, Radboud University Nijmegen Medical Centre and Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, The Netherlands.

**P 70. Retrospective Effectiveness of Deep Transcranial Magnetic Stimulation (DeepTMS) of the Prefrontal Cortex in a Cohort of 70 Patients with Drug resistant refractory Major Depression: An analysis by symptom**

Riquelme-Vejar R<sup>1</sup>, Fuentes C<sup>1</sup>, Villalon A.<sup>1</sup>, Villalon E<sup>1</sup>, Zamora S.<sup>2</sup>, Stehberg J<sup>1,3</sup>,

<sup>1</sup>NeuroClinic. Centro Médico Apoquindo, Las Condes, Santiago, Chile; <sup>2</sup>Centro de Salud Mental Integrada (CSMI), Providencia, Santiago, Chile; <sup>3</sup>Laboratorio de Neurobiología, Centro de Investigaciones Biomédicas, Universidad Andrés Bello, Santiago, Chile.



## SCIENTIFIC INFORMATION

### Audio-Visual Facilities

Speakers must go to the preview room in order to validate and download their presentation files, at least forty minutes before the beginning of the sessions.

Please respect this schedule, otherwise, the performance of the received presentations is not guaranteed.

We cannot accept presentations delivered in room directly (without previewing).

Coffee breaks and midday are the busiest time in the preview room. So we recommend you to come to the preview early in the morning or during other presentations. An hostess will guide and assist the speakers for checking and downloading their presentation files.

### European Accreditation

15 UEMS credits have been recognized for this Congress and these credits are recognized by the American Medical Association for conversion to AMA PRA Category 1 Credit.

### Certificate of Attendance

A certificate of attendance is provided by e-mail after the congress.

## GENERAL INFORMATION

### Admission

The participant's name badge is provided at the registration desk. All participants are requested to wear the badge throughout the congress. Only badge holders are admitted to the appropriate sessions, exhibition and social events

### Electricity

The standard voltage in Monaco is 220 V.

### Language

The official language of the Congress is English. No simultaneous translation will be provided.

### Secretariat

The secretariat desk will open on Wednesday, 20 November and stay open all through the Congress.

### Welcome cocktail

All delegates are cordially invited to attend the Welcome Cocktail of the Forum on Wednesday, 20 November at 18.00 in the Galerie Crystal of the Fairmont.

# 14<sup>th</sup> INTERNATIONAL FORUM ON MOOD AND ANXIETY DISORDERS

VIENNA, 05-07 NOVEMBER, 2014



*Save  
the date*

[www.ifmad.org](http://www.ifmad.org)

**CHAIRMAN** : Siegfried KASPER (Austria)

**CO-CHAIRMAN** : Stuart A. MONTGOMERY (United Kingdom)





# Cipralex<sup>®</sup> - the power to tackle depression<sup>1,2</sup>

## References:

1. Cipriani A et al. Lancet 2009;373:746-58
2. Kennedy SH et al. Curr Med Res Opin 2009;25(1):161-175

## CIPRALEX (escitalopram) - Abbreviated Prescribing Information

**Presentation** Film-coated tablets 5 10 15 20 mg, oral drops, solution 10 20 mg/ml and orodispersible tablets 10 20 mg. **Indication** Treatment of major depressive episodes; Treatment of panic disorder with or without agoraphobia; Treatment of social anxiety disorder (social phobia); Treatment of generalised anxiety disorder; Treatment of obsessive compulsive disorder. **Dosage Adults:** The recommended starting dose is 10 mg once daily. Depending on individual patient response the dose may be increased to a maximum of 20 mg once daily. An initial starting dose of 5 mg once daily is recommended in the treatment of elderly (>65 years), in panic disorder and in patients with reduced hepatic function. **Children and adolescents (< 18 years):** Cipralex should not be used. **Discontinuation:** Discontinue gradually over a period of at least one to two weeks to reduce the possibility of discontinuation symptoms. **Contraindications** Hypersensitivity to escitalopram or to any of the excipients. Patients with known QT interval prolongation or congenital long QT syndrome. In combination with MAO-inhibitors or with medicinal products known to prolong the QT interval. Should not be used during pregnancy unless clearly needed and after careful consideration of the risk/benefit. Breast-feeding is not recommended. **Precautions**

Depression is associated with an increased risk of suicidal thoughts, self-harm and suicide. It is a general clinical experience that the risk of suicide may increase in the early stages of recovery. Close supervision of high-risk patients should accompany drug therapy. Patients (and caregivers) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present. SSRIs should be avoided in patients with unstable epilepsy, and patients with controlled epilepsy should be closely monitored. SSRIs should be used with caution in patients with a history of mania/hypomania. Treatment with SSRIs may alter glycaemic control. Insulin and/or oral hypoglycaemic dosage may need to be adjusted. The use of SSRIs/SNRIs has been associated with the development of akathisia. Hyponatraemia has been reported rarely with the use of SSRIs. There have been reports of cutaneous bleeding abnormalities. There have been reports of QT interval prolongation and ventricular arrhythmia including torsade de pointes, predominantly in patients of female gender, with hypokalaemia, or with pre-existing QT interval prolongation or other cardiac diseases. **Interactions** Caution is advised when taken in combination with MAO-inhibitors or medicinal products known to prolong the QT interval, serotonergic medicinal products, products lowering the seizure threshold, lithium, tryptophan, St. John's Wort, oral anticoagulants or antiplatelet agents (NSAIDs), and products predominantly metabolised by the enzymes CYP2C19 and CYP2D6. **Undesirable effects** Adverse reactions are most frequent during the first or second week of treatment and usually decrease in intensity and

frequency with continued treatment. *Very common:* nausea. *Common:* decreased/increased appetite, weight increased, anxiety, restlessness, abnormal dreams, libido decreased, anorgasmia, insomnia, somnolence, dizziness, paraesthesia, tremor, sinusitis, yawning, diarrhoea, constipation, vomiting, dry mouth, sweating increased, arthralgia, myalgia, ejaculation disorder, impotence, fatigue and pyrexia. *Uncommon:* weight decreased, bruxism, agitation, nervousness, panic attack, confusional state, taste disturbance, sleep disorder, syncope, mydriasis, visual disturbance, tinnitus, tachycardia, epistaxis, gastrointestinal haemorrhages (including rectal haemorrhage), urticaria, alopecia, rash, pruritus, metrorrhagia, menorrhagia, oedema. *Rare:* anaphylactic reaction, aggression, depersonalisation, hallucination, serotonin syndrome, bradycardia. *Not known:* thrombocytopenia, inappropriate ADH secretion, hyponatraemia, anorexia, mania, suicidal ideation, suicidal behaviour, dyskinesia, movement disorder, convulsion, psychomotor restlessness/akathisia, electrocardiogram QT prolonged, ventricular arrhythmia including torsade de pointes, orthostatic hypotension, hepatitis, liver function test abnormal, ecchymosis, angioedemas, urinary retention, galactorrhoea, priapism. *Class effects:* Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fractures in patients receiving SSRIs. Overdose Cases of overdose with escitalopram doses between 400 mg and 800 mg have been reported without any severe symptoms. **Legal category** POM.

**Date of preparation or last review** August 2013  
**Full Prescribing Information is available from** H. Lundbeck A/S, Ørttilavej 9, 2500 Valby, Denmark

Lundbeck



**Cipralex<sup>®</sup>**  
escitalopram